
Oncotelic OT-101 meets safety and efficacy goals in Covid-19 trial
Oncotelic Therapeutics, Inc., a leading developer of TGF-β therapeutics for oncology and virology, today announced that its COVID-19 trial (“C001”) for OT-101 has successfully met its safety and efficacy endpoints. OT-101 is a first-in-class anti-TGF-β […]